Published in Eur J Nucl Med Mol Imaging on January 13, 2010
The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging (2010) 0.87
Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer. Eur J Nucl Med Mol Imaging (2011) 0.87
Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET. Q J Nucl Med Mol Imaging (2013) 0.83
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2011) 0.82
Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging. EJNMMI Phys (2014) 0.78
Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [(18)F]-tetrafluoroborate. EJNMMI Res (2015) 0.78
Clinical Studies of Nonpharmacological Methods to Minimize Salivary Gland Damage after Radioiodine Therapy of Differentiated Thyroid Carcinoma: Systematic Review. Evid Based Complement Alternat Med (2016) 0.78
Comparison of Imaging Characteristics of (124)I PET for Determination of Optimal Energy Window on the Siemens Inveon PET. Biomed Res Int (2016) 0.75
Partial-volume effect in PET tumor imaging. J Nucl Med (2007) 5.81
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med (2004) 1.76
Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med (2005) 1.73
Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med (2007) 1.72
Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nucl Med Commun (1996) 1.67
An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology (1998) 1.34
124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med (2009) 1.25
Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med (2000) 1.16
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med (2008) 1.14
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging (2007) 1.07
The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys (2006) 1.05
124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin (2007) 1.05
Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol) (2007) 1.00
Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Nucl Med Commun (2006) 0.97
An improved MCNP version of the NORMAN voxel phantom for dosimetry studies. Phys Med Biol (2005) 0.90
The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma. Q J Nucl Med Mol Imaging (2008) 0.85
[Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy]. Nuklearmedizin (1997) 0.85
REVISED AVERAGE GEOMETRIC FACTORS FOR CYLINDERS IN ISOTOPE DOSAGE. I. Radiology (1965) 0.80
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA (2003) 3.45
MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med (2009) 2.92
Euthyroid goiter with and without nodules--diagnosis and treatment. Dtsch Arztebl Int (2012) 2.79
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging (2009) 2.67
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol (2004) 2.23
Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging (2007) 2.23
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
False-positive FDG PET uptake--the role of PET/CT. Eur Radiol (2005) 1.97
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med (2004) 1.91
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology (2003) 1.90
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol (2003) 1.84
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med (2004) 1.81
Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med (2007) 1.73
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res (2011) 1.69
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61
Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol (2007) 1.59
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res (2006) 1.57
Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med (2012) 1.53
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med (2004) 1.51
¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging (2012) 1.50
Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology (2004) 1.48
Segmentation of PET volumes by iterative image thresholding. J Nucl Med (2007) 1.43
MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. Eur J Nucl Med Mol Imaging (2008) 1.42
Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging (2009) 1.41
MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med (2012) 1.40
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res (2004) 1.38
Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med (2010) 1.38
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med (2008) 1.37
Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA (2006) 1.29
Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest (2008) 1.28
Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med (2008) 1.28
Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med (2004) 1.27
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med (2011) 1.27
MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy. J Nucl Med (2008) 1.25
124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med (2009) 1.25
Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer (2004) 1.21
Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol (2013) 1.19
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging (2010) 1.17
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res (2010) 1.17
PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging (2006) 1.15
In vivo multicolor molecular MR imaging using diamagnetic chemical exchange saturation transfer liposomes. Magn Reson Med (2011) 1.15
Health-related Quality of Life, depression and anxiety in thyroid cancer patients. Qual Life Res (2006) 1.14
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med (2008) 1.14
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med (2002) 1.13
Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys (2008) 1.12
Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res (2009) 1.11
Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab (2002) 1.10
Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One (2012) 1.10
MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med (2003) 1.09
The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg (2010) 1.09
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med (2003) 1.09
Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med (2012) 1.08
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging (2007) 1.08
Murine S factors for liver, spleen, and kidney. J Nucl Med (2003) 1.07
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging (2007) 1.07
Efforts to control the errant products of a targeted in vivo generator. Cancer Res (2005) 1.06
Radiation dosimetry of 82Rb in humans under pharmacologic stress. J Nucl Med (2011) 1.06
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med (2004) 1.06
Renal dosimetry. Cancer Biother Radiopharm (2010) 1.06
Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer (2002) 1.05
Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol (2013) 1.05
Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. J Am Soc Nephrol (2005) 1.05
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res (2008) 1.04
Size-induced enhancement of chemical exchange saturation transfer (CEST) contrast in liposomes. J Am Chem Soc (2008) 1.03
Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med (2007) 1.03
Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med (2012) 1.03
German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg (2011) 1.02
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res (2003) 1.02
Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys (2009) 1.02
Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys (2006) 1.02
TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging (2007) 1.02
Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm (2002) 1.01
Lymph node staging with dual-modality PET/CT: enhancing the diagnostic accuracy in oncology. Eur J Radiol (2006) 1.00
Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract (2005) 1.00
A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol (2012) 1.00
Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med (2006) 1.00
SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med (2009) 1.00
Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur J Nucl Med Mol Imaging (2013) 0.99
Calculation of the biological effective dose for piecewise defined dose-rate fits. Med Phys (2009) 0.98
Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer (2009) 0.98
Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI. Eur J Radiol (2013) 0.97
Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Nucl Med Commun (2006) 0.97